Aribio Lab, formerly known as Cha Vaccine Research Institute, is set to unveil its plans for developing an Alzheimer's disease prevention vaccine ahead of a change in its major shareholder.
The company announced on November 10 that it will participate in the Korean Immunology Society International Conference (KAI 2026) from November 12 to 14 at Songdo Convensia in Incheon, where it will present its new pipeline for vaccines targeting degenerative brain diseases, including Alzheimer's, as well as developments in the anti-aging sector.
Aribio Lab will introduce its proprietary immune adjuvant platform technology and the current status of its key vaccine pipelines, along with plans for future projects in neuroimmunology and immune aging. A company representative stated, "We will reveal our vision to expand our business structure, which has focused on infectious disease vaccines, to include neuroimmunology and immune aging control."
The most advanced clinical pipeline is the recombinant shingles vaccine 'CVI-VZV-001.' It has completed the second administration in a Phase 2 clinical trial involving 135 adults aged 50 and older, with topline results expected in the first quarter of next year before entering Phase 3 trials.
The company is also broadening the scope of its platform applications. Aribio Lab is developing an mRNA-based immune cancer treatment as part of a national new drug development project. Additionally, it is working on South Korea's first recombinant Japanese encephalitis vaccine under a project funded by the Ministry of Health and Welfare.
The company emphasizes that its proprietary immune adjuvant platforms, 'L-pampo' and 'Lipo-pam,' are key competitive advantages. These technologies stimulate innate immune receptors TLR1/2 and TLR3 simultaneously, inducing both humoral and cellular immunity. They can be expanded for use in preventive vaccines, therapeutic vaccines, and immunotherapy.
Lipo-pam is the only technology from a domestic company listed in the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Coalition for Epidemic Preparedness Innovations (CEPI) 'Vaccine Adjuvant Library.' The company plans to pursue collaborative research and technology transfers with global vaccine developers based on this recognition.
Previously, Aribio completed a global Phase 3 clinical trial for its oral Alzheimer's treatment 'AR1001.' Detailed clinical results will be presented at the Alzheimer's Clinical Trials Conference (CTAD 2026) in Boston on November 16.
Building on this foundation, Aribio Lab aims to research preventive approaches to degenerative brain diseases and neuroimmunology modulation technologies, leveraging its experience in immune adjuvant platforms and vaccine development.
The company continues to advance its existing vaccine pipeline. The shingles vaccine 'CVI-VZV-001' has confirmed safety and a 100% seroprotection rate in Phase 1 trials and has completed administration in Phase 2 trials. The company plans to announce Phase 2 results in the first quarter of 2027 and pursue subsequent clinical development.
Jae-jun Jeong, CEO of Aribio Lab, stated, "The drug development capabilities of Aribio and the immune adjuvant platform of Aribio Lab are mutually complementary strengths, and we believe this will create new business opportunities that encompass both treatment and prevention."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.